A comprehensive and clinical‐oriented evaluation criteria based on DVH information and gamma passing rates analysis for IMRT plan 3D verification

Purpose To accomplish the 3D dose verification to IMRT plan by incorporating DVH information and gamma passing rates (GPs) (DVH_GPs) so as to better correlate the patient‐specific quality assurance (QA) results with clinically relevant metrics. Materials and methods DVH_GPs analysis was performed to specific structures of 51 intensity‐modulated radiotherapy (IMRT) treatment plans (17 plans each for oropharyngeal neoplasm, esophageal neoplasm, and cervical neoplasm) with Delta4 3D dose verification system. Based on the DVH action levels of 5% and GPs action levels of 90% (3%/2 mm), the evaluation results of DVH_GPs analysis were categorized into four regions as follows: the true positive (TP) (%DE> 5%, GPs